# 1 The sensitivity improved two-test algorithm "SIT<sup>2</sup>": a

## 2 universal optimization strategy for SARSAQ-CoV-2 serology

3	Thomas Perkmann MD* <sup>1</sup> , Thomas Koller MD* <sup>1</sup> , Nicole Perkmann-Nagele MD <sup>1</sup> , Maria Oszvar-Kozma
4	MSc <sup>1</sup> , David W Eyre DPhil <sup>2</sup> , Philippa Matthews DPhil <sup>3</sup> , Abbie Bown MD <sup>4</sup> , Nicole Stoesser DPhil <sup>3</sup> , Marie-
5	Kathrin Breyer MD PhD <sup>5</sup> , Robab Breyer-Kohansal MD <sup>5</sup> , Otto C Burghuber MD <sup>6</sup> , Sylvia Hartl MD <sup>5,6</sup> , Daniel
6	Aletaha MD <sup>7</sup> , Daniela Sieghart PhD <sup>7</sup> , Peter Quehenberger MD <sup>1</sup> , Rodrig Marculescu MD <sup>1</sup> , Patrick Mucher
7	MSc <sup>1</sup> , Astrid Radakovics MSc <sup>2</sup> , Miriam Klausberger PhD <sup>8</sup> , Mark Duerkop PhD <sup>9</sup> , Barbara Holzer PhD <sup>10</sup> ,
8	
0	Boris Hartmann PhD <sup>10</sup> , Robert Strassl MD <sup>1</sup> , Gerda Leitner MD <sup>11</sup> , Florian Grebien PhD <sup>12</sup> , Wilhelm Gerner
9	PhD <sup>13,14,15</sup> , Reingard Grabherr PhD <sup>8</sup> , Oswald F Wagner MD <sup>1</sup> , Christoph J Binder MD PhD <sup>1</sup> , and Helmuth
10	Haslacher MD PhD <sup>1*</sup>
11	<sup>1</sup> Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
12	<sup>2</sup> Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
13	<sup>3</sup> Nuffield Department of Medicine, University of Oxford, Oxford, UK
14	<sup>4</sup> Public Health England (PHE) Porton Down, Salisbury, UK
15	<sup>5</sup> Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital,
16	Vienna, Austria
17	<sup>6</sup> Sigmund Freud University, Medical School and Ludwig Boltzmann Institute for Lung Health, Vienna, Austria
18	<sup>7</sup> Divison of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
19	<sup>8</sup> Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU)
20	Vienna, Vienna, Austria
21	<sup>9</sup> Institute of Bioprocess Science and Engineering, Department of Biotechnology, University of Natural Resources and Life Sciences
22	(BOKU) Vienna, Vienna, Austria
23	<sup>10</sup> Institute for Veterinary Disease Control, Austrian Agency for Health and Food Safety (AGES), Moedling, Austria
24	<sup>11</sup> Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
25	<sup>12</sup> Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria
26	<sup>13</sup> Institute of Immunology, University of Veterinary Medicine Vienna, Austria
27	<sup>14</sup> Christian Doppler Laboratory for an Optimized Prediction of Vaccination Success in Pigs, University of Veterinary Medicine,
28	Vienna, Austria

- 29 <sup>15</sup>The Pirbright Institute, Pirbright, United Kingdom (current)
- 30 \*both authors contributed equally

- 31 Address all correspondence to:
- 32 Helmuth HASLACHER, LECT MD PhD MSc BSc BA
- 33 Medical University of Vienna
- 34 Department of Laboratory Medicine
- 35 Waehringer Guertel 18-20
- 36 1090 Vienna
- 37 Austria
- 38 Tel: +43 1 40400 53190
- 39 Fax: +43 1 40495 15547
- 40 Mail: <u>helmuth.haslacher@meduniwien.ac.at</u>

#### 41 Background

- 42 Reliable antibody tests are an essential tool to identify individuals who have developed
- 43 an adaptive immune response to SARS-CoV-2. However, attempts to maximize the
- 44 specificity of SARS-CoV-2 antibody tests have come at the cost of sensitivity,
- 45 exacerbating the total test error with increasing seroprevalence. Here, we present a
- 46 novel method to maximize specificity while maintaining or even increasing sensitivity: the
- 47 "Sensitivity Improved Two-Test" or "SIT<sup>2</sup>" algorithm.

#### 48 Methods

- 49 SIT<sup>2</sup> involves confirmatory re-testing of samples with results falling in a predefined
- 50 retesting-zone of an initial screening test, with adjusted cut-offs to increase sensitivity.
- 51 We verified and compared the performance of SIT<sup>2</sup> to single tests and orthogonal testing
- 52 (OTA) in an Austrian cohort (1,117 negative, 64 post-COVID positive samples) and
- 53 validated the algorithm in an independent British cohort (976 negatives, 536 positives).
- 54 **Results**
- 55 The specificity of SIT<sup>2</sup> was superior to single tests and non-inferior to OTA. The
- 56 sensitivity was maintained or even improved using SIT<sup>2</sup> when compared to single tests
- 57 or OTA. SIT<sup>2</sup> allowed correct identification of infected individuals even when a live virus
- 58 neutralization assay could not detect antibodies. Compared to single testing or OTA,
- 59 SIT<sup>2</sup> significantly reduced total test errors to 0 46% (0 24-0 65) or 1 60% (0 94-2 38) at
- 60 both 5% or 20% seroprevalence.

#### 61 Conclusion

SIT<sup>2</sup> proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all
tested scenarios. It is an easy algorithm to apply to different available SARS-CoV-2

- 64 antibody testing systems and can potentially be helpful for the serology of other
- 65 infectious diseases.

#### 66 Introduction

67 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to a

68 worldwide pandemic confronting us with unprecedented epidemiological, therapeutic,

69 but not at last diagnostic challenges.

70 While case identification focuses primarily on polymerase chain reaction (PCR) or

antigen testing, detecting antibodies to SARS-CoV-2 is essential to identify individuals

72 who develop a SARS-CoV-2-specific adaptive immune response following infection or

vaccination. So, reliable determination of SARS-CoV-2 antibodies can provide critical

74 information for healthcare decision-making (1). Accurate measurement of antibody

75 levels is paramount in estimating seroprevalences because subsequent attempts to

compensate for antibody test errors can result in highly variable estimates of the actual

seroprevalence rates(2). Moreover, antibody positivity has also been shown to correlate

78 with protective immunity(3, 4) and several quantitative assays have been used to

79 determine vaccine-induced antibody levels(5, 6).

80 Current test systems measure antibodies against either the SARS-CoV-2 nucleocapsid 81 (NC) or spike (S) protein or fragments thereof(7). For correct serological results, both 82 high specificity and sensitivity are crucial. The suboptimal specificities of some of the 83 early SARS-CoV-2 antibody tests were problematic in the context of the low 84 seroprevalence at the onset of the pandemic. This has changed rapidly, and currently 85 available SARS-CoV-2 antibody tests are amongst the most specific serological tests 86 available. In addition, despite marked regional differences, global seroprevalence has 87 increased significantly(8). Unfortunately, the claim by many test manufacturers that 88 assay sensitivities are close to 100% has proven to be inaccurate and too optimistic in

89 practice(7, 9). Two major possible reasons underlying this are that: i) lower antibody 90 levels in non-hospitalized mild or asymptomatic cases sometimes fall below 91 manufacturers' cut-offs, which are set to optimize specificity to limit false-positive 92 results(10, 11), and ii) the decline in antibody titers over time towards the positivity 93 threshold increases the demands on assay sensitivity (12, 13). The latter phenomenon is 94 dependent on the test system used(14, 15) and can be a considerable problem, as 95 shown by an epidemiological study from Brazil(2). 96 Consequently, maximizing both the sensitivity and specificity of SARS-CoV-2 serology is 97 essential. However, there has been no attempt to optimize both parameters 98 simultaneously through a systematic approach to our knowledge. Generally, there is a 99 trade-off between sensitivity and specificity for a given test depending on the selected 100 threshold for positivity; increasing specificity to near 100% comes at the expense of 101 sensitivity, and vice versa. Attempts to increase sensitivity by lowering thresholds for 102 positivity below the recommended values set by manufacturers lead to unacceptably low 103 specificities. Orthogonal testing algorithms (OTA), as recommended by the Center for 104 Disease Control (CDC) for low seroprevalence settings, increase specificity at the 105 expense of sensitivity(16). Although this recommendation was justified at the beginning 106 of the pandemic, it is no longer appropriate given the significant increase in 107 seroprevalence in most areas of the world and the known sensitivity problem of SARS-108 CoV-2 antibody tests and contributes to the rise in the overall error rate. 109 In this paper, we present a new, simple, and widely applicable method, the Sensitivity-110 Improved Two-Test (SIT<sup>2</sup>) algorithm, which, for the first time, allows the maximization of 111 specificity while maintaining or even increasing sensitivity.

#### 112 Methods

#### 113 Study design and cohorts

114 Sera used in this non-blinded prospective cross-sectional study were either residual

115 clinical specimens or samples stored in the MedUni Wien Biobank (n=1,181), a facility

specialized in the preservation and storage of human biomaterial, which operates within

117 a certified quality management system (ISO 9001:2015)(17).

118 For derivation of the SIT<sup>2</sup> algorithm, sample sets from individuals known to be negative

and positive were established for testing. As previously described(11), samples collected

120 before 01.01.2020 (i.e., assumed SARS-CoV-2 negative) were used as a specificity

121 cohort (n=1117): a cross-section of the Viennese population (the LEAD study)(18),

122 preselected for samples collected between November and April to enrich for seasonal

123 infections (n=494); a collection of healthy voluntary donors (n= 265); a disease-specific

124 collection of samples from patients with rheumatic diseases (n=358); (see also Tables

125 S1 and S2).

126 Of the SARS-CoV-2 positive cohort (n=64 samples from n=64 individuals), five

127 individuals were asymptomatic, 42 had mild-moderate symptoms, four reported severe

symptoms, and 13 were admitted to the Intensive Care Unit (ICU). The timing of

129 symptom onset was determined by a questionnaire for convalescent donors and by

130 reviewing individual health records for patients. For asymptomatic donors (n=5), SARS-

131 CoV-2 RT-PCR confirmation time was used instead (for more details, see Tables S1 and

132 S3). All included participants gave written informed consent to donate their samples for

133 research purposes. The overall evaluation plan conformed with the Declaration of

134 Helsinki as well as relevant regulatory requirements. It was reviewed and approved by

the ethics committee of the Medical University of Vienna (1424/2020).

136 For validation of the SIT<sup>2</sup> algorithm, we used data from an independent United Kingdom

137 cohort(19), including 1,512 serum/plasma samples (536 PCR confirmed SARS-CoV-2

138 positive cases; 976 negative cases, collected earlier than 2017).

#### 139 Antibody testing

140 For the derivation analyses, SARS-CoV-2 antibodies were either measured according to

141 the manufacturers' instructions on three different commercially available automated

142 platforms (Roche Elecsys® SARS-CoV-2 [nuclecapsid total antibody assay, further

143 referred to as Roche NC], Abbott SARS-CoV-2-IgG assay [nucleocapsid IgG assay,

144 Abbott NC], DiaSorin LIASION® SARS-CoV-2 S1/S2 assay [S1/S2 combination antigen

145 IgG assay, DiaSorin S1/S2]) or using 96-well enzyme-linked immunosorbent assays

146 (ELISAs) (Technoclone Technozym® RBD and Technozym® NP) yielding quantitative

147 results(20) (for details see Supplement, Supplemental Methods). The antibody assays

148 used in the validation cohort were Abbott NC, DiaSorin S1/S2, Roche NC, Siemens RBD

total antibody, and a novel 384-well trimeric spike protein ELISA (Oxford

150 Immunoassay)(19), resulting in 20 evaluable combinations. All samples from the

151 Austrian SARS-CoV-2-positive cohort also underwent live virus neutralization testing

152 (VNT), and neutralization titers (NT) were calculated, as is described in detail in the

153 Supplemental Methods.

#### 155 Sensitivity improved two-test method (SIT<sup>2</sup>)

156 Our newly developed sensitivity improved two-test (SIT<sup>2</sup>) method consists of the

- 157 following key components: i) sensitivity improvement by cut-off modification and ii)
- 158 specificity rescue by a second, confirmatory test (Fig. 1A).

159 For the first component of the SIT<sup>2</sup> algorithm, positivity thresholds were optimized for

160 sensitivity according to the first published alternative thresholds for the respective

assays(21-23). Additionally, a high cut-off, above which a result can be reliably regarded

162 as true positive without the need for further confirmation, was defined. These levels were

163 based on in-house observations(11). The lowering of positivity thresholds improves

sensitivity; the high cut-off prevents unnecessary re-testing of clearly positive samples.

165 Moreover, the high cut-off avoids possible erroneous exclusion by the confirmatory test.

166 The newly defined interval between the reduced threshold for positivity and the high cut-

167 off is the re-testing zone (Fig. 1A). The initial antibody test (screening test) is then

168 followed by a confirmatory test, whereby positive samples from the re-testing zone of the

169 screening test are re-tested. Also, for the confirmatory test, sensitivity-adapted assay

170 thresholds are needed (Figs.1A, 1B). As false-positive samples are usually only positive

171 in one test system (Fig. S1), false positives can be identified, and specificity markedly

172 restored with minimal additional testing as most samples do not fall within the re-testing

173 zone(11, 24). A flowchart of the testing strategy and the applied cut-off levels and their

174 associated quality criteria are presented in Figs. 1B, 1C.

#### 175 Test strategy evaluation

176 On the derivation cohort, we compared the overall performance of the following SARS-

177 CoV-2 antibody testing strategies: i) testing using single assays; ii) simple lowering of

thresholds; iii) classical orthogonal testing (OTA), and iv) our newly developed SIT<sup>2</sup> 178 179 algorithm at assumed seroprevalences of 5% and 20%. As part of the derivation, we then compared the performance of OTAs and SIT<sup>2</sup> against the results of a virus 180 181 neutralization assay. On the validation cohort, we then compared the performance of OTAs and SIT<sup>2</sup>. Finally, we used data from this cohort to evaluate the performance of 182 SIT<sup>2</sup> versus single tests at seroprevalences of 5%, 10%, 20%, and 50% if the Abbott and 183 184 DiaSorin assays (i.e., assays with varying degrees of discrepancies in sensitivity and 185 specificity) were used.

#### 186 Statistical analysis

187 Unless otherwise indicated, categorical data are given as counts (percentages), and 188 continuous data are presented as median (interguartile range). Total test errors were 189 compared by Mann-Whitney tests or, in case they were paired, by Wilcoxon tests. 95% 190 confidence intervals (CI) for sensitivities and specificities were calculated according to 191 Wilson, 95% CI for predictive values were computed according to Mercaldo-Wald unless 192 otherwise indicated. Sensitivities and specificities were compared using z-scores. P 193 values <0.05 were considered statistically significant. All calculations were performed 194 using Analyse-it 5.66 (Analyse-it Software, Leeds, UK) and MedCalc 19.6 (MedCalc 195 byba, Ostend, Belgium). Graphs were drawn using Microsoft Visio (Armonk, USA) and 196 GraphPad Prism 7.0 (La Jolla, USA).

#### 197 **Results**

- 198 Based on the derivation cohort of 1,117 pre-pandemic sera and 64 sera from
- 199 convalescent COVID-19 patients (80% non-hospitalized, 20% hospitalized), the Roche
- 200 NC, Abbott NC, and DiaSorin S1/S2 antibody assays gave rise to 545, 780, and 860
- false-negative results per 100,000 tests, and 285, 760 and 1,710 false-positive results
- 202 per 100,000 tests respectively, assuming a seroprevalence of 5% (Fig. 2A, left panel).
- 203 Effects of threshold lowering on Sensitivity and Specificity

Lowering the positivity thresholds for the Roche NC, Abbott NC, and Diasorin S1/S2 to 17%, 38% and 75% of the manufacturers cut-offs increased the sensitivity significantly and reduced false-negative results to 80, 155, and 545 per 100,000 tests, respectively, but substantially increased false-positive results to 1,520, 2,280 and 2,660 per 100,000 tests respectively (all at an assumed seroprevalence of 5%; Table S4, Fig. 2A, left panel).

#### 210 Classical OTA compared to SIT<sup>2</sup>

211 Subsequently, we evaluated 12 OTA combinations using the fully automated SARS-212 CoV-2 antibody tests from Roche NC, Abbott NC, and DiaSorin S1/S2 as screening 213 tests, each combined with one of the other fully automated assays or a commercially 214 available NC or RBD-specific ELISA as a confirmation test. Combining these tests as 215 classical OTAs significantly increased specificity and reduced false positives to 0 (0-95) 216 per 100,000 tests. However, the rate of false negatives was 1,095 (955-1,230) per 217 100,000 tests, and therefore considerably higher than for single testing strategies. In contrast, the SIT<sup>2</sup> algorithm minimized false positives to 0 (0-166 25) per 100,000 tests 218

while also reducing false negatives to 390 (235-607.5) per 100,000 tests (Fig. 2A left
panel; Table S5).

221 At an assumed seroprevalence of 20%, the consequences of reduced test sensitivities 222 led to an even more substantial rise in false-negative results for all testing strategies 223 (Fig. 2A, right panel). Both SIT<sup>2</sup> and OTA reduced false-positive results substantially compared to single testing strategies (SIT<sup>2</sup>: 0 [0-140] and OTA: 0 [0-80] false-positives 224 per 100,000 tests). However, SIT<sup>2</sup> achieved a substantially lower rate of false-negative 225 results when compared to OTA (1,560 [940-2,420] vs 4,380 [3,820-4,920] per 100,000 226 tests). The reduction in false-positive results using SIT<sup>2</sup> compared to single tests with 227 228 the manufacturers' recommended thresholds (Table S6) was accompanied by a lower 229 average false-negative rate for SIT2 than for single tests (Fig. 2A, right panel). Even at 230 20% seroprevalence, single tests resulted in a non-negligible number of false positives 231 (240, 640, and 1,440 per 100,000 tests).

#### 232 Reduction of total error rates by the Sensitivity-Improved Two-Test

Of all the methods assessed, SIT<sup>2</sup> reached the lowest total error rates per 100.000 tests 233 234 under both 5% and 20% assumed seroprevalence (455 [235-685] and 1,600 [940-2,490] 235 per 100,000 tests) (Fig. 2B). At a seroprevalence of 5 %, OTA on average performed 236 better than individual tests, and the total error rates of the single tests were higher for 237 the Abbott NC and DiaSorin S1/S2 assay (OTA 1,095 [955-1,325] vs. 830 [Roche NC]. 238 1,540 [Abbott NC] and 2,570 [DiaSorin S1/S2] per 100,000 tests). But with a 239 seroprevalence of 20 %, performance of OTAs, worsened compared to single tests 240 (OTA 4.380 [3.820-5.000] vs 1.600 [Roche], 2.540 [Abbott] and 4.420 [DiaSorin] per 100,000 tests) (Fig. 2B). Therefore, at both 5% and 20% seroprevalence, SIT<sup>2</sup> resulted 241

in the lowest overall errors. Compared to OTAs, SIT<sup>2</sup> yielded a similar improvement in
specificity while not suffering from the significant sensitivity reduction (Fig. S2). Since the
better overall performance of SIT<sup>2</sup> compared to OTAs was not due to increased
specificity but improved sensitivity, we subsequently set out to examine these
differences in more detail.

247 Sensitivities of single tests, OTA and SIT2 in relation to Neutralization Testing

248 Next, we compared the sensitivities of the three screening tests as single tests and in

both two-test methods (OTA and SIT<sup>2</sup>), benchmarking them using the Austrian

250 sensitivity cohort (n=64) simultaneously evaluated with an authentic SARS-CoV-2 virus

251 neutralization test (VNT). Regardless of the screening test used (Roche NC, Abbott NC,

or DiaSorin S1/S2), OTAs had lower sensitivities than single tests (80 5% [78 5-83 6],

253 78 1% [75 8-82 8], or 75 8% [71 5-78 9] vs. 89 1%, 84 4%, or 82 8% respectively), and

254 SIT<sup>2</sup> showed the best sensitivities of all methods (95 3% [93 0-96 5], 93 8% [92 2-96 5],

or 87 5% [85 1-88 7]) (Fig. 3). SIT<sup>2</sup> algorithms, including the Roche NC and Abbott NC

assays, achieved similar or even higher sensitivities than VNT (Fig. 3, VNT reference

line), made possible by the unique re-testing zone of SIT<sup>2</sup> (Fig. S3).

258 Validation of the Sensitivity-Improved Two-Test using an independent cohort

259 To confirm the improved sensitivity of SIT<sup>2</sup> compared to OTA, we analyzed the

sensitivities of OTAs and SIT<sup>2</sup> in an independent validation cohort of 976 pre-pandemic

samples and 536 post-COVID samples. Out of 20 combinations using the assays Roche

262 NC (total antibody), Abbott NC (IgG), DiaSorin S1/S2 (IgG), Siemens RBD (total

antibody), and Oxford trimeric-S (IgG), a statistically significant improvement in

sensitivities over OTAs was shown for SIT<sup>2</sup> in 18 combinations (Fig. 4). The

265	performance was comparable for the remaining two combinations (Siemens RBD with
266	Oxford trimeric-S and vice versa). Still, no statistically significant improvement could be
267	achieved due to the high pre-existing sensitivities of these assays on this particular
268	sample cohort.
269	To further illustrate the effect of $SIT^2$ on the outcome of SARS-CoV-2 antibody testing,
270	we compared single testing versus SIT <sup>2</sup> with the Abbott and DiaSorin assays at varying
271	assumed seroprevalences (5, 10, 20, and 50%), given that the Abbott NC assay is a
272	highly specific (99.9%), but moderately sensitive test (92.7%), and the DiaSorin S1/S2 $$
273	assay has the most limited specificity (98-7%) of all evaluated assays but an acceptable
274	sensitivity (96-3%). Regardless of whether a lack of specificity (DiaSorin S1/S2) or
275	sensitivity (Abbott NC) had to be compensated for, SIT <sup>2</sup> improved the overall error rate
276	compared to the individual tests in all four combinations and at all four assumed
077	

277 seroprevalence levels (Fig. 5).

#### 278 **Discussion**

279	The simplest and most	practical way to	characterize the immune	response to prior

- 280 SARS-CoV-2 infection and vaccination is to measure SARS-CoV-2-specific antibodies.
- As long as the COVID-19 pandemic continues, serology-based assays' ongoing use and
- 282 development will play a role in controlling and surveillance of this disease. The
- importance and value of SARS-CoV-2 antibody assays are well established(1, 3, 25-27),
- although some performance limitations may affect their applicability. To date, variable
- seroprevalence and very low antibody levels, especially in asymptomatic or mild
- disease(10), have challenged the performance of available tests(9, 11).

287 In the present work, we first sought to overcome these limitations by lowering positivity

thresholds to improve test sensitivity(21-23, 28) or by using conventional orthogonal

testing to maximize specificity(16, 29-32). As recommended by the CDC and used in

several seroprevalence studies(31, 33), OTAs indeed maximized specificity and thus

291 minimized false-positive results in the two sample cohorts evaluated, regardless of

whether the assumed seroprevalence was 5% or 20%. However, this was accompanied

293 by a further reduction of the a priori sub-optimal sensitivities of individual tests and

increased false negatives, as shown previously(16). In seroprevalence studies,

insufficient sensitivities can lead to apparent discrepancies. This is exemplified in a large

study in Iceland, where only slightly more than 90% of individuals testing positive for

297 SARS-CoV-2 by RT-PCR were seropositive(33), resulting from a priori low sensitivities

of the single tests used or the OTA applied, or a combination of both.

Reducing the cut-offs for positivity leads to a significant increase in sensitivity, also
shown previously(2, 21, 22), but is associated with a dramatic increase in false-positive

301 results at low seroprevalence. This effect only gradually decreases with increasing302 seroprevalence (Fig. 5).

303 The rates of false positives, false negatives, and overall errors of test systems depend 304 on their specificity and sensitivity and the respective seroprevalence in the population. At 305 a population level, at low seroprevalences, a test system with suboptimal specificity 306 combined with insufficient sensitivity can add up to a correctly determined 307 seroprevalence rate since false-positive, and false-negative results can compensate for 308 each other (Fig. S2, left panel). However, at an individual level, the determination of 309 serostatus in such a context is highly flawed, making individual-level results unreliable 310 and unsuitable for management and subgroup analyses. For single tests, specificity and 311 sensitivity always behave in opposite ways since an increase in the positivity threshold 312 increases the specificity but lowers the sensitivity and vice versa. Low test specificity 313 leads to a significant increase in the overall error rate at low seroprevalence. Low test 314 sensitivity leads to a substantial increase in the overall error rate at high seroprevalence. 315 However, since seroprevalence is often neither known and varies widely from region to 316 region, it is difficult to judge whether a less specific or less sensitive test is the lesser of 317 two evils.

To overcome these limitations, we propose a new, universally adaptable two-test system that can perform better than any other known approach regardless of the actual seroprevalence: the sensitivity-improved Two-Test or SIT<sup>2</sup>. Its generalizability can be inferred from the following features: i) the adapted cut-offs used to optimize sensitivity were determined in various independent studies and were not explicitly calculated for our cohort(21-23); ii) SIT<sup>2</sup> was effective, albeit with different efficiencies, in a total of 32

different test combinations; and iii) SIT<sup>2</sup> was successfully validated in an independent
cohort which was profoundly different from the derivation cohort. Therefore, SIT<sup>2</sup> does
not require a particular infrastructure or the availability of high-performance individual
test systems but achieves the best performance out of an available test.

328 Our SIT<sup>2</sup> strategy can rescue the specificity with minimal repeat testing required (see 329 Table S6). For example, when applying the Roche NC as a screening test to our cohort, 330 only 27 out of 1,181 samples needed confirmation testing with the Abbott NC test to 331 correctly identify 62/64 true positives. Simultaneously, all false-positive results were 332 eliminated, including those added by lowering the cut-offs (Table S4 and Fig. S1). 333 Additionally, it was more sensitive than virus neutralization testing, which identified only 334 60/64 clinical positives (Fig. 3). This result is not completely surprising as it is known that 335 not all patients who recovered from COVID-19 show detectable levels of neutralizing 336 antibodies(34). Nevertheless, it should be noted that although antibody binding assays 337 may have a higher sensitivity than neutralization assays, they only partially reflect the 338 functional activity of SARS-CoV-2-reactive antibodies(35, 36).

339 In addition to the low or absent antibody formation shortly after COVID-19 infection(10, 340 34), the antibody levels also decline over time(14), and this is dependent on the assay 341 used. For example, an antibody-positivity half-life of ~85 days has been specifically 342 described for the Abbott NC test(15). The decrease in antibody levels or antibody 343 reactivity measured in specific assays can lead to a status of "seroreversion" in post-344 COVID-19 individuals. While some of this disappearance may reflect a genuine loss of 345 antibody (i.e., true seroreversion), some of it reflects an artifact caused by the decline of 346 antibody levels below assay positivity thresholds, as remarkably illustrated in a recent

Brazilian study. The seroprevalence (measured by Abbott NC) apparently decreased
from 46% to just under 21% between June 2020 and October 2020, when the
manufacturer's recommended cut-off of 1 4 S/C was applied. In contrast, the same test
results with a threshold reduced to 0 4 S/C yielded ~54% seroprevalence in June 2020
and around 45% in October 2020(2).

352 Our study has both strengths and limitations. One strength is the size of the cohorts examined, both in deriving the SIT<sup>2</sup> algorithm (N=1,181) and validating it (N=1,512). The 353 354 composition of our specificity cohort is also unique: it consists of three sub-cohorts with 355 selection criteria to further challenge analytical specificity. The lower cut-offs used to 356 increase sensitivity were not modeled within our datasets but were derived from ROC-357 analyses data of independent studies (21-23). Furthermore, we were able to test the 358 performance of the two-test systems in a total of 32 combinations, 12 in the derivation 359 cohort and another 20 combinations in the validation cohort. As a limitation, in the 360 Austrian cohort, only samples ≥14 days after symptom onset were included. Therefore, 361 no conclusions on the sensitivity of the early seroconversion phase can be made from 362 these data. Furthermore, mild and asymptomatic cases were underrepresented in the 363 British cohort, perhaps leading to an observed higher sensitivity of the test systems. In conclusion, we describe the novel two-test algorithm SIT<sup>2</sup> that, in contrast to classical 364 365 orthogonal testing, can simultaneously maximize the specificity and the sensitivity of 366 SARS-CoV-2 antibody tests. Poor sensitivity remains a problem for SARS-CoV-2 367 antibody tests. Low a priori antibody levels in many post-COVID-19 individuals 368 combined with the steady antibody decline over time reduce effective sensitivity and

369 lead to many errors in the assignment of SARS-CoV-2 serostatus. In the early post-

- 370 vaccine era of the pandemic, reliable assignation of SARS-CoV-2 serostatus will
- 371 become even more relevant to public health and infection control policy. With SIT<sup>2</sup>, we
- 372 present a platform-independent and straightforward solution to minimize the overall error
- 373 rate in determining SARS-CoV-2 antibody presence at the individual and population
- 374 level, thereby increasing the accuracy of subsequent decisions.

#### 375 Acknowledgments

We sincerely thank Marika Gerdov, Susanne Keim, Karin Mildner, Elisabeth Ponweiser,
Manuela Repl, Ilse Steiner, Christine Thun, and Martina Trella for excellent technical
assistance. Finally, we want to thank all the donors of the various study cohorts. The
MedUni Wien Biobank is funded to participate in the biobank consortium BBMRI.at
(www.bbmri.at) by the Austrian Federal Ministry of Science, Research and Technology.
There was no external funding received for the work presented. However, test kits for
the Technoclone ELISAs were kindly provided by the manufacturer.

#### 383 **Declaration of interests**

384 NP received a travel grant from DiaSorin. DWE reports lecture fees from Gilead outside 385 the submitted work. OCB reports grants from GSK, grants from Menarini, grants from 386 Boehringer Ingelheim, grants from Astra, grants from MSD, grants from Pfizer, and 387 grants from Chiesi, outside the submitted work. SH does receive unrestricted research 388 grants (GSK, Boehringer, Menarini, Chiesi, Astra Zeneca, MSD, Novartis, Air Liquide, 389 Vivisol, Pfizer, TEVA) for the Ludwig Boltzmann Institute of COPD and Respiratory 390 Epidemiology, and is on advisory boards for G. SK, Boehringer Ingelheim, Novartis, 391 Menarini, Chiesi, Astra Zeneca, MSD, Roche, Abbvie, Takeda, and TEVA for respiratory 392 oncology and COPD. PQ is an advisory board member for Roche Austria and reports 393 personal fees from Takeda outside the submitted work. The Dept. of Laboratory 394 Medicine (Head: OWF) received compensations for advertisement on scientific 395 symposia from Roche, DiaSorin, and Abbott and holds a grant for evaluating an in-vitro 396 diagnostic device from Roche. CJB is a Board Member of Technoclone. HH receives

397 compensations for biobank services from Glock Health Science and Research and398 BlueSky immunotherapies.

#### 399 **References**

- 400 1. Alter G, Seder R. The Power of Antibody-Based Surveillance. N Engl J Med 2020
- 401 Oct 29;383 18:1782-4. Epub 2020/09/02 as doi: 10.1056/NEJMe2028079.
- 402 2. Buss LF, Prete CA, Jr., Abrahim CMM, Mendrone A, Jr., Salomon T, de Almeida-
- 403 Neto C, Franca RFO, et al. Three-quarters attack rate of SARS-CoV-2 in the
- 404 Brazilian Amazon during a largely unmitigated epidemic. Science 2021 Jan

405 15;371 6526:288-92. Epub 2020/12/10 as doi: 10.1126/science.abe9728.

- 406 3. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB,
- 407 Marsden BD, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in
- 408 Health Care Workers. N Engl J Med 2020 Dec 23. Epub 2020/12/29 as doi:
- 409 10.1056/NEJMoa2034545.
- 410 4. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B,
- 411 et al. Single-dose administration and the influence of the timing of the booster
- 412 dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine:
- 413 a pooled analysis of four randomised trials. Lancet 2021;397 10277:881—91 as

414 doi: 10.1016/s0140-6736(21)00432-3 PMID - 33617777.

- 415 5. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, Jesuthasan G, et al.
- 416 Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-
- 417 AstraZeneca vaccines by previous infection status. Clin Microbiol Infect 2021 Jun
- 418 7. Epub 2021/06/11 as doi: 10.1016/j.cmi.2021.05.041.

- 419 6. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A,
- 420 Marculescu R, Wolzt M, et al. Anti-Spike Protein Assays to Determine SARS-
- 421 CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
- 422 Microbiol Spectr 2021 Jun 30:e0024721. Epub 2021/07/01 as doi:
- 423 10.1128/Spectrum.00247-21.
- 424 7. Wang H, Ai J, Loeffelholz MJ, Tang YW, Zhang W. Meta-analysis of diagnostic
- 425 performance of serology tests for COVID-19: impact of assay design and post-
- 426 symptom-onset intervals. Emerg Microbes Infect 2020 Dec;9 1:2200-11. Epub
- 427 2020/09/24 as doi: 10.1080/22221751.2020.1826362.
- 428 8. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, Yanes-Lane M, et al.
- 429 Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and
- 430 meta-analysis. Plos One 2021;16 6:e0252617. Epub 2021/06/24 as doi:
- 431 10.1371/journal.pone.0252617.
- 432 9. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, Shenhar
- 433 Y, et al. Multi-center nationwide comparison of seven serology assays reveals a
- 434 SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine
- 435 2020 Dec;29:100651. Epub 2020/11/26 as doi: 10.1016/j.eclinm.2020.100651.
- 436 10. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, et al. Clinical and
- 437 immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med
- 438 2020 Aug;26 8:1200-4. Epub 2020/06/20 as doi: 10.1038/s41591-020-0965-6.
- 439 11. Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber
- 440 OC, Hartl S, Aletaha D, et al. Side-by-Side Comparison of Three Fully Automated
- 441 SARS-CoV-2 Antibody Assays with a Focus on Specificity. Clin Chem 2020 Nov
- 442 1;66 11:1405-13. Epub 2020/08/11 as doi: 10.1093/clinchem/hvaa198.

443 1	2.	Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, Kim NJ, et al. Antibody
-------	----	---

- 444 Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. Emerg
- 445 Infect Dis;27 3:928-31 as doi: 10.3201/eid2703.204543 PMID 33350923.
- 446 13. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, et
- 447 al. Longitudinal observation and decline of neutralizing antibody responses in the
- 448 three months following SARS-CoV-2 infection in humans. Nat Microbiol;5

449 12:1598-607 as doi: 10.1038/s41564-020-00813-8 PMID - 33106674.

- 450 14. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire
- 451 J, et al. Longitudinal analysis of serology and neutralizing antibody levels in
- 452 COVID19 convalescents. J Infect Dis 2020 Nov 3. Epub 2020/11/04 as doi:
- 453 10.1093/infdis/jiaa659.
- 454 15. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch
- 455 SB, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody
- 456 responses in individual healthcare workers. Clin Infect Dis 2021 Jan 6. Epub
- 457 2021/01/06 as doi: 10.1093/cid/ciab004.
- 458 16. Turbett SE, Anahtar M, Dighe AS, Garcia Beltran W, Miller T, Scott H, Durbin SM,
- 459 et al. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their
- 460 Performance in Two-Test Algorithms. J Clin Microbiol 2020 Dec 17;59 1. Epub
  461 2020/10/07 as doi: 10.1128/JCM.01892-20.
- 462 17. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M,
- 463 Hidalgo LG, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated
- 464 Kidney Transplant Rejection [eng]. J Am Soc Nephrol 2018 Feb;29 2:591-605.
- 465 Epub 2017/12/16 as doi: 10.1681/asn.2017070818.

466 18. Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Scl
--

- 467 Sigsgaard T, et al. The LEAD (Lung, Heart, Social, Body) Study: Objectives,
- 468 Methodology, and External Validity of the Population-Based Cohort Study. J
- 469 Epidemiol 2019 Aug 5;29 8:315-24. Epub 2018/10/23 as doi:
- 470 10.2188/jea.JE20180039.
- 471 19. National S-C-SAEG. Performance characteristics of five immunoassays for
- 472 SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020
- 473 Dec;20 12:1390-400. Epub 2020/09/27 as doi: 10.1016/S1473-3099(20)30634-4.
- 474 20. Klausberger M, Duerkop M, Haslacher H, Wozniak-Knopp G, Cserjan-
- 475 Puschmann M, Perkmann T, Lingg N, et al. A comprehensive antigen production
- 476 and characterisation study for easy-to-implement, specific and quantitative SARS-
- 477 CoV-2 serotests. Ebiomedicine 2021 Apr 24;67:103348. Epub 2021/04/28 as doi:
- 478 10.1016/j.ebiom.2021.103348.
- 479 21. Favresse J, Eucher C, Elsen M, Tre-Hardy M, Dogne JM, Douxfils J. Clinical
- 480 Performance of the Elecsys Electrochemiluminescent Immunoassay for the
- 481 Detection of SARS-CoV-2 Total Antibodies. Clin Chem 2020 Aug 1;66 8:1104-6.
- 482 Epub 2020/06/03 as doi: 10.1093/clinchem/hvaa131.
- 483 22. Lau CS, Oh HML, Hoo SP, Liang YL, Phua SK, Aw TC. Performance of an
- 484 automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta 2020
- 485 Nov;510:760-6. Epub 2020/09/11 as doi: 10.1016/j.cca.2020.09.005.
- 486 23. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, et al.
- 487 Clinical and Analytical Performance of an Automated Serological Test That
- 488 Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J Clin
- 489 Microbiol 2020 Aug 24;58 9. Epub 2020/06/26 as doi: 10.1128/JCM.01224-20.

490	24.	Pfluger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Norz D, van der
491		Meirschen M, et al. Clinical evaluation of five different automated SARS-CoV-2
492		serology assays in a cohort of hospitalized COVID-19 patients. J Clin Virol 2020
493		Sep;130:104549. Epub 2020/08/09 as doi: 10.1016/j.jcv.2020.104549.
494	25.	Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P,
495		Parsonnet J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide
496		sample of patients on dialysis in the USA: a cross-sectional study. Lancet 2020
497		Sep 25. Epub 2020/09/29 as doi: 10.1016/S0140-6736(20)32009-2.
498	26.	Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda
499		M, Sanmartin JL, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a
500		nationwide, population-based seroepidemiological study. Lancet 2020 Aug
501		22;396 10250:535-44. Epub 2020/07/10 as doi: 10.1016/S0140-6736(20)31483-
502		5.
503	27.	Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder
504		D, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,
505		Switzerland (SEROCoV-POP): a population-based study. Lancet 2020 Aug 1;396
506		10247:313-9. Epub 2020/06/15 as doi: 10.1016/S0140-6736(20)31304-0.
507	28.	Horber S, Soldo J, Relker L, Jurgens S, Guther J, Peter S, Lehmann R, et al.
508		Evaluation of three fully-automated SARS-CoV-2 antibody assays. Clin Chem
509		Lab Med 2020 Aug 3;58 12:2113-20. Epub 2020/08/04 as doi: 10.1515/cclm-
510		2020-0975.
511	29.	Xu G, Emanuel AJ, Nadig S, Mehrotra S, Caddell BA, Curry SR, Nolte FS, et al.
512		Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG

513 Antibodies. Clin Chem 2020 Sep 7. Epub 2020/09/08 as doi:

514 10.1093/clinchem/hvaa210.

- 515 30. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA,
- 516 Thompson MR, et al. Orthogonal SARS-CoV-2 Serological Assays Enable
- 517 Surveillance of Low-Prevalence Communities and Reveal Durable Humoral
- 518 Immunity. Immunity 2020 Nov 17;53 5:925-33 e4. Epub 2020/11/02 as doi:

519 10.1016/j.immuni.2020.10.004.

520 31. Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, Deeks SL, et al.

521 SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid

522 antibody decline. J Infect Dis 2021 Jan 5. Epub 2021/01/06 as doi:

523 10.1093/infdis/jiaa796.

524 32. Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S, Pizzini A, et al.

525 Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests

526 suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clin Chem Lab Med

527 2021 Jan 14;0 0. Epub 2021/02/09 as doi: 10.1515/cclm-2020-1758.

- 528 33. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson
- 529 E, Arnthorsson AO, et al. Humoral Immune Response to SARS-CoV-2 in Iceland.
- 530 N Engl J Med 2020 Oct 29;383 18:1724-34. Epub 2020/09/02 as doi:
- 531 10.1056/NEJMoa2026116.

532 34. Kalkan Yazici M, Koc MM, Cetin NS, Karaaslan E, Okay G, Durdu B, Sumbul B,

533 et al. Discordance between Serum Neutralizing Antibody Titers and the Recovery

534 from COVID-19. J Immunol 2020 Nov 15;205 10:2719-25. Epub 2020/09/27 as

535 doi: 10.4049/jimmunol.2000840.

- 536 35. Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C,
- 537 Paul A, et al. Evaluation of high-throughput SARS-CoV-2 serological assays in a
- 538 longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity
- and association with virus neutralization test. Clin Chem 2021 Jan 5. Epub
- 540 2021/01/06 as doi: 10.1093/clinchem/hvaa336.
- 541 36. Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, Bozzato D, et
- al. Analytical and clinical performances of five immunoassays for the detection of
- 543 SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine
- 544 2020 Dec;62:103101. Epub 2020/11/08 as doi: 10.1016/j.ebiom.2020.103101.

#### 546 Figure Legends


- 547 **Fig. 1. A)** The Sensitivity Improved Two-Test (SIT<sup>2</sup>) algorithm includes sensitivity
- 548 improvement by adapted cut-offs and a subsequent specificity rescue by re-testing all
- samples within the re-testing zone of the screening test by a confirmatory test. **B**)
- 550 Testing algorithm for SIT<sup>2</sup> utilizing a screening test on an automated platform
- 551 (ECLIA/Roche, CMIA/Abbott, CLIA/DiaSorin) and a confirmation test, either on one of
- the remaining platforms or tested by means of ELISA (Technozym RBD, NP). C) All test
- 553 results between a reduced cut-off suggested by the literature, and a higher cut-off,
- above which no more false-positives were observed, were subject to confirmation
- testing. \*\*... results between 12 0 and 15 0, which are according to the manufacturer
- 556 considered borderline, were treated as positives; \*\*\*... suggested as a cut-off for
- 557 seroprevalence testing; \*\*\*\*... determined by in-house modeling; <sup>1</sup>... see (21); <sup>2</sup>... see

558 (22); <sup>3</sup>... see (23).


- 559 Fig. 2. False-positives (FP)/false-negatives (FN) (A) and total error (B) of single tests,
- tests with reduced thresholds according to (21-23), orthogonal testing algorithms (OTAs)
- 561 and the Sensitivity Improved Two-Test (SIT<sup>2</sup>) algorithm at 5 and 20% estimated
- 562 seroprevalence. Data in (B) were compared by Mann-Whitney tests (unpaired) or
- 563 Wicoxon tests (paired). \*... P<0.05; \*\*...P<0.01; \*\*\*...P<0.001.
- Fig. 3. Sensitivities of single tests, orthogonal testing algorithms (OTAs) and the
  Sensitivity Improved Two-Test (SIT<sup>2</sup>) algorithm. The dotted line indicates the sensitivity
  of virus neutralization test (VNT).
- Fig. 4. Differences in sensitivity and specificity (mean±95% confidence interval) between
   the Sensitivity Improved Two-Test (SIT<sup>2</sup>) algorithm and standard orthogonal testing

- 569 algorithms (OTAs) within the UK validation cohort. \*... P<0 05; \*\*...P<0 01;
- 570 \*\*\*...*P*<0 001; \*\*\*\*...*P*<0 0001
- 571 Fig. 5. Comparing false-positives (FP), false-negatives (FN), and total error (TE) for two
- 572 selected test systems, A) Abbott, B) DiaSorin, between different Sensitivity Improved
- 573 Two-Test (SIT<sup>2</sup>) combinations and the respective single test within the UK validation
- 574 cohort for different estimated seroprevalences.

# A **Step 1: Sensitivity Improvement**




# **Step 2: Specificity Rescue**





# B

Screening test antibody levels

	Roche	Abbott	DiaSorin	Technozym RBD	Technozym NP
Sensitivity	89.1 (79.1-94.6)	84.4 (73.6-91.3)	82.8 (71.8-90.1)	85.9 (75.4-92.4)	78.1 (66.6-86.5)
Specificity	99.7 (99.2-99.9)	99.2 (98.5-99.6)	98.2 (97.3-98.8)	99.2 (98.5-99.6)	99.1 (98.4-99.5)
PPV (5%)	94.6 (84.9-98.2)	84.6 (74.0-91.4)	70.9 (60.2-79.2)	84.9 (74.4-91.6)	82.1 (71.0-89.6)
NPV (5%)	99.4 (98.9-99.7)	99.2 (98.6-99.5)	99.1 (98.4-99.5)	99.3 (98.7-99.6)	98.9 (98.2-99.3)
Cut-off (manufacturer)	1.000 COI	1.40 I	12.0 AU/mL**	8.000 U***	8.000 U***
Reduced Cut-off	>0.165 <sup>1</sup>	≥0.55 <sup>2</sup>	≥9.0 <sup>3</sup>	>3.000 U****	>3.500 U****
High Cut-off	3.000	3.00	150.0	-	-








False positives/negatives


### B


**Total error** (5% seroprevalence estimated) \*\* \*\* \*\*\* 6,000 per 100,000 tests [N] False results 4,000 2,000 1% 0 Standard Reduced SIT<sup>2</sup> OTA cut-offs cut-offs

Total error (20% seroprevalence estimated)




### Sensitivity with standard testing, OTA and SIT<sup>2</sup>





Δ SIT<sup>2</sup> - OTA

# A Abbott



**B** DiaSorin

